Cancer diagnostics developer ANGLE (LON: AGL) is getting nearer to FDA approval for its Parsortix liquid biopsy test. Angle would be the first company to receive FDA Class II clearance for a device harvesting intact circulating tumour cells CTC), making the technology highly valuable.
The specific approval would cover breast cancer. Clearance would allow Parsortix to be used in drug trials as well as the continued monitoring of patients who have been successfully treated.
Parsortix can capture circulating tumour cells, which can then be analysed.
FDA approval
It always seems to take lo...
